Barbivet vet 60 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

barbivet vet 60 mg tabletti

vetoquinol s.a. - phenobarbital - tabletti - 60 mg - fenobarbitaali

Lidocaine Baxter 10 mg/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

lidocaine baxter 10 mg/ml injektioneste, liuos

baxter holding b.v. - lidocaine hydrochloride - injektioneste, liuos - 10 mg/ml - lidokaiini

Riximyo Euroopan unioni - suomi - EMA (European Medicines Agency)

riximyo

sandoz gmbh - rituksimabi - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiset aineet - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. on vain vähän tietoa turvallisuudesta ja tehosta potilailla, joita on aiemmin hoidettu monoklonaalisia vasta-aineita, mukaan lukien rituksimabi tai potilaat eivät sietäneet aiemman rituksimabi plus kemoterapiaa. ks. kohta 5. 1 lisätietoja. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabi on todettu hidastavan etenemistä nivelvaurioita mitattuna x-ray ja parantaa fyysistä toimintakykyä, kun sitä annetaan yhdessä metotreksaatin kanssa. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

MIP SM Suomi - suomi - Ecolab

mip sm

ecolab deutschland gmbh -

Tramat Suomi - suomi - Fimea (Suomen lääkevirasto)

tramat

bayer ag -

Octostim 150 mikrog/annos nenäsumute, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

octostim 150 mikrog/annos nenäsumute, liuos

ferring lÄÄkkeet oy - desmopressin acetate - nenäsumute, liuos - 150 mikrog/annos - desmopressiini

KETOFEN RETARD 200 mg depotkapseli Suomi - suomi - Fimea (Suomen lääkevirasto)

ketofen retard 200 mg depotkapseli

generics (uk) limited - ketoprofenum - depotkapseli - 200 mg - ketoprofeeni

Cemisiana 0,03 mg / 2 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

cemisiana 0,03 mg / 2 mg tabletti, kalvopäällysteinen

sandoz a/s - ethinylestradiol, dienogest - tabletti, kalvopäällysteinen - 0,03 mg / 2 mg - dienogesti ja etinyyliestradioli